- Nucleus RadioPharma is developing two new facilities, totaling over 100,000 square feet, to advance radiopharmaceutical production and accessibility.
- The expansion aims to cut drug development timelines by up to 30% and improve patient access to life-saving treatments.
Nucleus RadioPharma has announced plans to build two new facilities in Mesa, Arizona, and Springhouse, Pennsylvania, totaling over 100,000 square feet. These sites will integrate research, development, and commercial production, providing key advantages for the radiopharmaceutical industry.
The expansion seeks to address major challenges in the sector, such as the shortage of high-quality manufacturing capabilities and geographic constraints caused by the short half-life of radiopharmaceuticals. The new facilities are designed to improve patient access by enabling production closer to clinical trial sites and treatment centres.
“Our expansion will significantly improve patient access to these life-saving treatments and expedite clinical trials, potentially reducing time-to-market for new therapies by up to 30%,” said Charles S. Conroy, CEO of Nucleus RadioPharma.
The Mesa site, measuring 53,000 square feet, and the 48,000-square-foot Springhouse facility are strategically located to serve key markets. Partners such as Fox Chase Cancer Center and Mayo Clinic stand to benefit from the scale and proximity of these sites.
The development is also set to bring economic growth, creating new jobs in each location. Mesa Mayor John Giles welcomed the investment, noting that it will enhance the local economy and reinforce the region’s status as an innovation hub.
Read about the Radiopharmaceutical CDMO Market here.
 Overview of outsourcing trends 
